Prospective Open Uncontrolled Phase I Study of Compatibility, Safety and Pharmacokinetics of Artesunate, a Semisynthetic Derivative of Artemisinin From the Chinese Herb Artemisia Annua in Patients With Metastatic/Locally Advanced Breast Cancer.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Artesunate (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
Most Recent Events
- 01 Aug 2017 Biomarkers information updated
- 14 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 15 Jan 2010 Planned number of patients changed from 18 to 19 as reported by ClinicalTrials.gov.